Ery-ped Suspension
NDC Package 24338-130-13

11-digit billing NDC: 24338013013 · Billing unit: ML · 100 ML per package

Package Information

Ery-ped (erythromycin ethylsuccinate) suspension is to reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This formulation utilizes a suspension delivery system. Marketed by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), this product is identified by NDC 24338-130 and is authorized under FDA application NDA050207.

Identification & Billing

NDC Package Code
24338-130-13
Package Description
100 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
24338013013
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
100 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ery-ped
Non-Proprietary Name
Erythromycin Ethylsuccinate
Substance Name
Erythromycin Ethylsuccinate
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae,or Haemophilus influenzae(when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzaeare not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniaeor Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenesor Staphylococcus aureus(resistant staphylococci may emerge during treatment).

Regulatory & Marketing

Labeler Name
Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
Product Type
Human Prescription Drug
FDA Application #
NDA050207
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-14-2012
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24338-130-13 identifies a specific commercial package of 100 ml in 1 bottle of Ery-ped, a human prescription drug labeled by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals). This suspension is formulated for oral use and contains erythromycin ethylsuccinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) on June 14, 2012. The current certification is valid through December 31, 2026.

How is this Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24338013013. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24338-130-13
11-Digit CMS (5-4-2)
24338-0130-13

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.